FDA's AI Risk -Based Guidance Shifts Validation Burden to Sponsors
FDA's AI Risk -Based Guidance shifts validation burden to sponsors, requiring documented credibility assessments before deploying AI in clinical ...
Read the original at The Clinical Trial Vanguard ↗
- Topics
- Healthcare
- Mentions
- FDA
- Tracked via
- “AI Risks”